An experimental vaccine against the severe acute respiratory syndrome (SARS) virus has elicited a strong immune response against the virus in a test on monkeys, the vaccine’s developers report.
Immunologist Andrea Gambotto and his colleagues at the University of Pittsburgh School of Medicine devised a vaccine using three common-cold adenoviruses, each genetically modified to produce a protein from the coronavirus that causes SARS.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.